|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
WO1996013593A2
(en)
|
1994-10-26 |
1996-05-09 |
Procept, Inc. |
Soluble single chain t cell receptors
|
|
WO1996018105A1
(en)
|
1994-12-06 |
1996-06-13 |
The President And Fellows Of Harvard College |
Single chain t-cell receptor
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6451995B1
(en)
|
1996-03-20 |
2002-09-17 |
Sloan-Kettering Institute For Cancer Research |
Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
|
|
CA2305630C
(en)
|
1997-10-02 |
2012-11-06 |
Sunol Molecular Corporation |
Soluble single-chain t-cell receptor proteins
|
|
NZ507886A
(en)
|
1998-05-19 |
2003-05-30 |
Avidex Ltd |
Multivalent T cell receptor complexes
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6940003B1
(en)
*
|
1998-12-03 |
2005-09-06 |
E. I. Du Pont De Nemours And Company |
Plan lecithin: cholesterol acyltransferases
|
|
GB9912350D0
(en)
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
WO2001049274A2
(en)
|
1999-12-30 |
2001-07-12 |
Chiron Corporation |
Methods for pulmonary delivery of interleukin-2
|
|
CA2410510A1
(en)
|
2000-06-02 |
2001-12-13 |
Memorial Sloan-Kettering Cancer Center |
Artificial antigen presenting cells and methods of use thereof
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
FI117667B
(fi)
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
PT1421115E
(pt)
|
2001-08-31 |
2005-07-29 |
Avidex Ltd |
Receptor de celulas t soluvel
|
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
|
EP2130919A1
(en)
|
2001-11-05 |
2009-12-09 |
ZymoGenetics, Inc. |
IL-21 antagonists
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
AU2003271904B2
(en)
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
EP2048159B1
(en)
|
2002-11-09 |
2014-01-01 |
Immunocore Ltd. |
T cell receptor display
|
|
WO2004044006A1
(en)
|
2002-11-14 |
2004-05-27 |
Maxygen, Inc. |
Conjugates of interleukin-10 and polymers
|
|
GB0304068D0
(en)
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
NZ550815A
(en)
|
2004-05-19 |
2009-04-30 |
Immunocore Ltd |
Method of improving T cell receptors
|
|
WO2005113595A2
(en)
|
2004-05-19 |
2005-12-01 |
Avidex Ltd |
High affinity ny-eso t cell receptor
|
|
EP1791865B1
(en)
|
2004-06-29 |
2010-07-28 |
Immunocore Ltd. |
Cells expressing a modified t cell receptor
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
AU2006237329B2
(en)
|
2005-04-18 |
2012-04-12 |
Novo Nordisk A/S |
IL-21 variants
|
|
WO2006125962A2
(en)
|
2005-05-25 |
2006-11-30 |
Medigene Limited |
T cell receptors which specifically bind to vygfvracl-hla-a24
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
|
EP2087000A2
(en)
|
2006-09-29 |
2009-08-12 |
Immunocore Ltd. |
T cell therapies
|
|
EP2109620B1
(en)
|
2006-12-21 |
2012-08-22 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
CA2749558C
(en)
|
2008-12-08 |
2019-01-15 |
Complix Nv |
Single-chain antiparallel coiled coil proteins
|
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
US20120107267A1
(en)
|
2009-03-11 |
2012-05-03 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
WO2011044186A1
(en)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Human single-chain t cell receptors
|
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
|
ES2905545T3
(es)
*
|
2010-01-06 |
2022-04-11 |
Takeda Pharmaceuticals Co |
Proteínas de unión a calicreína plasmática
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
RU2013139267A
(ru)
|
2011-02-10 |
2015-03-20 |
Рош Гликарт Аг |
Улучшенная иммунотерапия
|
|
WO2012129514A1
(en)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
EA201892619A1
(ru)
*
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
WO2013071154A1
(en)
|
2011-11-11 |
2013-05-16 |
Fred Hutchinson Cancer Research Center |
Cyclin a1-targeted t-cell immunotherapy for cancer
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
NZ702108A
(en)
|
2012-05-03 |
2016-09-30 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
MY177331A
(en)
*
|
2012-06-15 |
2020-09-12 |
Pfizer |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
PL3434695T3
(pl)
|
2012-08-07 |
2021-05-17 |
Roche Glycart Ag |
Ulepszona immunoterapia
|
|
WO2014023709A1
(en)
*
|
2012-08-09 |
2014-02-13 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
RU2729401C2
(ru)
|
2012-10-02 |
2020-08-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
|
US9562110B2
(en)
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
KR102493543B1
(ko)
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
DK3189081T3
(da)
*
|
2014-09-05 |
2020-05-04 |
Janssen Pharmaceutica Nv |
Cd123-bindende midler og anvendelser deraf
|
|
WO2016100375A2
(en)
|
2014-12-15 |
2016-06-23 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
RU2740672C2
(ru)
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
AU2016312259B2
(en)
|
2015-08-26 |
2018-12-06 |
Bison Therapeutics Inc. |
Multispecific antibody platform and related methods
|
|
JP7014724B2
(ja)
|
2016-02-06 |
2022-02-01 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
タンデム型Fab免疫グロブリンおよびその使用
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
CU24483B1
(es)
|
2016-11-15 |
2020-04-02 |
Ct Inmunologia Molecular |
Método para incrementar los niveles de secreción de la interleucina-2
|
|
WO2018106972A1
(en)
|
2016-12-07 |
2018-06-14 |
La Jolla Institute For Allergy And Immunology |
Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
ES2985986T3
(es)
|
2017-01-06 |
2024-11-08 |
Bicyclerd Ltd |
Conjugado biciclo para tratar el cáncer
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
TW201919662A
(zh)
|
2017-06-05 |
2019-06-01 |
美商艾歐凡斯生物治療公司 |
對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
|
|
WO2018236010A1
(ko)
|
2017-06-23 |
2018-12-27 |
주식회사 글로원 |
비대칭구조의 보습 마스크팩
|
|
US20200306301A1
(en)
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
CN110997013B
(zh)
|
2017-07-24 |
2022-09-20 |
瑞泽恩制药公司 |
抗cd8抗体和其用途
|
|
SG11202000820PA
(en)
|
2017-07-31 |
2020-02-27 |
Tizona Therapeutics |
Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
|
|
CN118126157A
(zh)
|
2017-08-03 |
2024-06-04 |
美国安进公司 |
白介素-21突变蛋白和治疗方法
|
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
|
JP2020533971A
(ja)
|
2017-08-28 |
2020-11-26 |
アルター・バイオサイエンス・コーポレーション |
Il−15をベースとするil−7及びil−21への融合物
|
|
US11970537B2
(en)
|
2017-12-26 |
2024-04-30 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody Fc region as backbone and use thereof
|
|
MX2020007291A
(es)
|
2018-01-12 |
2020-09-10 |
Amgen Inc |
Anticuerpos anti-pd-1 y metodos de tratamiento.
|
|
CN111655717A
(zh)
|
2018-01-26 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
IL-22 Fc融合蛋白及使用方法
|
|
MX387358B
(es)
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
KR20260100427A
(ko)
|
2018-03-28 |
2026-06-29 |
오리오니스 바이오사이언시즈 인코포레이티드 |
이작용성 단백질 및 이의 작제물
|
|
CA3095498A1
(en)
|
2018-04-09 |
2019-10-17 |
Origincell Therapeutics Co., Ltd. |
Anti-pd-l1 antibody and use thereof
|
|
AU2019288496B2
(en)
|
2018-06-22 |
2024-11-21 |
Cugene Inc. |
Interleukin-2 variants and methods of uses thereof
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
US12522640B2
(en)
|
2018-07-24 |
2026-01-13 |
BioNTech SE |
IL2 agonists
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
KR20210057124A
(ko)
|
2018-09-11 |
2021-05-20 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 용도
|
|
CN112105634B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
CA3098930A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
|
CA3117853A1
(en)
|
2018-10-29 |
2020-05-07 |
1Globe Biomedical Co., Ltd. |
Novel rationally designed protein compositions
|
|
TW202031284A
(zh)
|
2018-11-08 |
2020-09-01 |
美商新索思股份有限公司 |
介白素10結合物及其用途
|
|
US20220025007A1
(en)
|
2018-12-21 |
2022-01-27 |
Hanmi Pharm. Co., Ltd. |
Novel immunosuppressive interleukin 2
|
|
CN113924311A
(zh)
|
2019-01-07 |
2022-01-11 |
印希比股份有限公司 |
包含修饰的il-2多肽的多肽及其用途
|
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7778571B2
(ja)
|
2019-06-05 |
2025-12-02 |
アッシャー バイオセラピューティクス, インコーポレイテッド |
免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
|
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
|
|
EP4175979A2
(en)
|
2020-07-02 |
2023-05-10 |
Inhibrx, Inc. |
Polypeptides comprising modified il-2 polypeptides and uses thereof
|
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
|
AU2021396247A1
(en)
*
|
2020-12-09 |
2023-07-06 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
|
|
JP2023553216A
(ja)
|
2020-12-09 |
2023-12-20 |
アシャ バイオセラピューティクス,インク. |
遺伝子操作細胞療法のための標的化サイトカイン構築物
|
|
WO2022135469A1
(zh)
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
白细胞介素21突变体以及其用途
|
|
WO2022245500A1
(en)
|
2021-05-19 |
2022-11-24 |
Asher Biotherapeutics, Inc. |
Il-21 polypeptides and targeted constructs
|
|
KR20230044130A
(ko)
|
2021-09-24 |
2023-04-03 |
바이오엔시스템스 주식회사 |
Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
|
|
WO2023052846A2
(en)
|
2021-09-30 |
2023-04-06 |
Ildong Pharmaceutical Co., Ltd. |
Immunocytokine containing il-21r mutein
|
|
CN119546343A
(zh)
|
2022-04-27 |
2025-02-28 |
亚设生物治疗公司 |
细胞因子融合蛋白与cd8抗原结合分子的组合
|